Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

NAMSW

NewAmsterdam Pharma Comp... (NAMSW)

NewAmsterdam Pharma Company NV
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:NAMSW
일자시간출처헤드라인심볼기업
2024/06/1121:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/06/1121:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark OfficeNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/06/0805:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/06/0805:01GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/05/2921:00GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in JuneNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/05/2121:00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/05/1005:18Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/05/1005:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/05/0921:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/05/0921:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/05/0905:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/05/0405:01GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/05/0221:00GlobeNewswire Inc.NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/04/0921:00GlobeNewswire Inc.NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/04/0121:00GlobeNewswire Inc.NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/03/2521:00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/03/1221:00GlobeNewswire Inc.NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/02/2822:00GlobeNewswire Inc.NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/02/2622:00GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/02/1412:40GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/02/1406:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/02/0206:01GlobeNewswire Inc.NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/01/0822:00GlobeNewswire Inc.NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of DirectorsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/01/0422:00GlobeNewswire Inc.NewAmsterdam Pharma Announces 2024 Strategic PrioritiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2023/11/1322:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial HighlightsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2023/10/2321:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2023/09/2120:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 MutationNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2023/09/2021:00GlobeNewswire Inc.NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2023/08/1505:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2023/08/0720:15GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial HighlightsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
 검색 관련기사 보기:NASDAQ:NAMSW

최근 히스토리

Delayed Upgrade Clock